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 ABSTRACT 
 
Cancer is the major cause of death around the world that needs to be controlled and 
treated. Studies around bioactive compounds extracted from natural products 
demonstrated their great potentials as experiment targets for cancer therapies. However, 
the potential mechanism of action of anticancer compounds through regulating cellular 
signal transduction pathways and inducing cancer cell death via autophagy or apoptosis 
is not fully revealed. Specific targets in cell transduction pathways, NF-κB and HDACs, 
and autophagy pathways attract more attention in present researches around the 
mechanism of action bioactive compounds with anti-cancer activities. In this review, by 
concluding recent five years publications, it is believed that NF-κB, HDACs and 
autophagy pathways are essential targets for studies around bioactive compounds. 
Future studies may focus more on bioactive compounds that target multiple pathways 
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Cancer is expected to rank as the leading cause of death and the single most important barrier to 
increasing life expectancy in every country of the world in the 21st century. According to estimates 
from the World Health Organization (WHO) in 2015, cancer is the first or second leading cause 
of death before age 70 years in 91 of 172 countries, and it ranks third or fourth in an additional 22 
countries (Bray F., et al., 2018). The International Agency for Research on Cancer provides a status 
report estimating the cancer incidence and mortality on the global burden of cancer worldwide in 
2018. The report deduced that 8.1 million new cancer cases (17.0 million excluding nonmelanoma 
skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) 
arouse in 2018. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to 
occur in the United States. While thinking positively, the overall cancer death rate dropped 
continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer 
cancer deaths than would have been expected if death rates had remained at their peak (Siegel, R. 
L., et al., 2019). 
The drop in the death rate can partially prove that people are trying to find treatments against 
cancer development. More and more mechanisms of tumorigenesis on cell levels have been 
revealed, which help researchers to develop treatments like drugs and chemotherapies that target 
signaling transduction pathways of tumor cells against cancer progression. Since early detection 
and effective treatment help increase survival rates of cancer patients (Nosrati, N., et al., 2017), 
prevention and treatment of cancer at early stages more promising. Due to the toxicity and damage 
caused by chemical synthesis products, people turn to extract functional compounds from natural 
products. Studies proved that fruits and vegetables can provide a wide variety of nutrients and a 
8 
 
range of bioactive compounds including vitamins (vitamin C, folate, and provitamin A), minerals 
(potassium, calcium, and magnesium), phytochemicals (flavonoids, phenolic acids, alkaloids, and 
carotenoids), and fibers (Liu, R. H., 2004). More and more evidence suggested that high 
consumption of fruits and vegetables is strongly associated with reduced risk of developing chronic 
diseases like cancer (Liu, R. H., 2013). 
“Bioactive compounds” are extra-nutritional constituents that typically occur in small quantities 
in foods. They are proved to be valuable in the therapy of human health, for example, various 
studies have shown protective effects of plant-based diets on cancer (Kris-Etherton, P. M., et al., 
2002). Curcumin, the main active compound from turmeric, has a wide spectrum of 
pharmacological activities upon multiple biological targets in preventing tumor initiation, 
progression, and dissemination in a number of human cancers (Zhang, P., et al., 2017). Diallyl 
trisulfide (DATS), a bioactive compound derived from vegetables, has been investigated as an 
anti-cancer and prove to arrest cancer cells at multiple stages of the cell cycle (Puccinelli, M., et 
al., 2017). Ursolic acid, proved to exhibit anticancer activity, anti-inflammatory effects, and 
induction of apoptosis in several human cancer cells, in particularly, inhibiting breast cancer 
proliferation by inducing cell G1/G2 arrest and regulating the expression of key proteins in signal 
transduction pathways, as well as inducing apoptosis in human breast cancer cells through intrinsic 
and extrinsic apoptotic pathways (Yin, R., et al., 2018). Various bioactive compounds appear to 
have benefits on anti-cancer treatments via modulating on multiple cell transduction pathways. 
 Recently, the increasing amount of studies around bioactive compounds and their mechanism on 
tumor cell signaling transduction pathways involved in regulating NF-κB, HDACs activities and 
modulating autophagy pathways. 
9 
 
NF-κB, a nuclear factor that binds to the enhancer element of the immunoglobulin kappa light-
chain of activated B cells (Sen, R., et al.,1986), identified as a transcription factor family with five 
members, designated as p65 (RelA), RelB, c-Rel, NF-κB1 and NF-κB2 (Hoesel, B., et al., 2013). 
It is a key element for controlling the expression of hundreds of genes involved in immunity, 
inflammation, proliferation, and in defense against apoptosis (Chandrashekar, N., et al., 2012). 
Therefore, NF-κB is a great target for designing anti-cancer drugs, and more and more bioactive 
compounds in recent research are proved to regulate NF-κB transduction pathways. It is necessary 
to sort out commonly mechanisms of action of bioactive compounds modulating on NF-κB 
activities. 
Autophagy, as an ATP-dependent physiological process that, together with other forms of 
regulated cell death, is involved in normal cytoplasmic turnover and in many important cellular 
functions (Levine, B., et al., 2004). It is also implicated in the rearrangement of cellular membranes, 
in the control of programmed cell death mechanisms, and in all those processes in which the seized 
material is carried, degraded, and recycled inside the lysosomes (Reggiori, F., et al., 2002). It can 
play a role in different types of diseases, such as cancer (Giampieri F., et al., 2019). Through its 
pro-survival and pro-death functions, autophagy can be related to a different stage of cancer 
development. Multiple studies give positive evidence to support the connection between bioactive 
compounds and induction of autophagy. Hence, relative intact mechanisms of action of bioactive 
compounds inducing autophagy are needed to be concluded as well. 
Tumorgenesis is the consequences of both genetic and epigenetic alteration of the cell (Singh BN., 
et al., 2010). There is a rapidly emerging field that explores the link between diet and gene 
interactions called nutritional genomics (Vahid, F., et al., 2015). While, epigenetics is defined by 
the heritable changes in gene expression that does not involve alterations in the DNA sequence 
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(Voss, T. C., et al., 2014). Histone acetylation provides a critical mechanism for epigenetic control 
of gene expression (Choudhary, C., et al., 2009). The chromatin is where histone deacetylases 
(HDACs) deacetylate histones and alter electrostatic properties of chromatin in a manner that 
favors gene repression. Based on phylogenetic similarity, HDACs have been categorized into four 
classes, Class I (HDAC1, 2, 3, and 8); II (HDAC4, 5, 6, 7, 9, and 10); and IV (HDAC11). In recent 
years, studies have shown that HDACs have arisen as important therapeutic targets for various 
diseases (Patil M., et al, 2017). For cancer cells, uncontrolled growth can lead by deregulation of 
HDAC activity due to aberrant expression or recruitment to promoter regions (Singh BN., et al., 
2010). So controlling the activities of HDACs is believed to be an effective mechanism of action 
of bioactive compounds to regulating tumor cells genesis and promotion. 
This review mainly concludes recent five years of research about bioactive compounds’ treatment 
via autophagy pathways, signaling pathways of NF-κB and histone deacetylase (HDAC) and their 














BIOACTIVE COMPOUNDS ON INDUCING NF-κB  INHIBITION 
As a transcriptional factors that involved in both inflammation and cell apoptosis, NF-κB regulates 
a wide array of cancer-related genes, which includes survival genes like Bcl-2, TRAP, p53, and 
Fas 211-213; angiogenetic gene like VEGF (vascular endothelial growth factor); energy 
metabolism gene GLUT3; and invasive and metastatic genes like MMP (matrix 
metalloproteinases), ICAM-1(intercellular adhesion molecule 1, namely, CD54), ELAM-1 
(endothelial-leukocyte adhesion molecule 1), and VCAM-1 (vascular cell adhesion molecule 1) 
(Chen, H., Liu, R. H., 2018). In most quiescent cells NF-κB dimers are bound to inhibitory 
molecules of the IκB family of proteins (inhibitors of NF-κB), which will further associate with 
the DNA-binding domains of the transcription factors thereby making them transcriptionally 
inactive. But It can be activated by the degradation of IκB, which leads to NF-κB be constitutively 
activated in many types of cancer and exert a variety of pro-tumorigenic functions. Meanwhile, 
NF-κB can also regulate the induction of proinflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α). On the other hand, the addition of TNF-α stimuli can cause the activation of the 
inhibitors of IκB kinase (IKK), which are the major upstream regulators of NF-κB (Suh, J., et al., 
2004). Once IKKs are activated and phosphorylated, they in turn cause phosphorylation and 
proteasomal degradation of IκBα, thus leaving the free active form of NF-κB for nuclear 
localization. Furthermore, studies confirmed that TNF-α can induce NF-κB’s translocation from 
the cytoplasm into the nucleus (Yemelyanov, A., et al., 2006). As we described above, those key 
factors involved in the regulation of NF-κB were further demonstrated to be modulated by various 
bioactive compounds in recent discoveries. 
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6-Shogaol (6-SHO), a potent bioactive compound in ginger, is proved to inhibit TNF-a–induced 
phosphorylation of NF-κB in all three human prostate cancer cells (Saha, A., et al., 2014). 
Immunocytochemical data proved 6-SHO's ability to block the NF-κB localization into the nucleus. 
Also, inhibition of NF-κB was accompanied by inhibition of NF-kB downstream targets, such as 
cyclin D1, survivin, and cMyc. 6-SHO treatment at two doses (50 and 100 mg/kg) both inhibited 
the growth of HMVP2 cells without any obvious toxic reactions, which proved the potential ability 
of 6-SHO as a natural therapeutic agent in prostate cancer. 
Lipopolysaccharide (LPS), as one of the stimuli, can trigger IκBα degradation, was found to be 
reduced by Longan flower and seed extracts treatment (Kunworarath, N., et al., 2016). With 1μg 
mL-1 of LPS treatments, the addition of Longan flower and seed extracts significantly increasing 
the IκBα degradation activity, which proves that phytochemicals in Logan extracts’ potential on 
inhibited cancer through inhibition of NF-κB activation. 
Pinus roxburghii essential oil (PREO), was researched on multiple cell lines, i.e. HCT-116 (colon 
cancer), KBM-5 (myelogenous leukemia) (Sajid A., et al, 2018). Results proved that PREO can 
regulate the TNF-α- induced NF-κB activation on dose-dependent to its concentration. Gene 
products involved in tumor cells survival, which downregulated by NF-κB activities, was also 
proved to be down-regulated by increasing the PREO concentration at a concentration of 100 
μg/mL. Their research proved the value of PREO as anticancer, anti-inflammatory agents. 
Huang and his team extracted a compound from Euphorbia sieboldiana, which found to diminish 
the intracellular NF-κB and translocated into the nucleus from the cytoplasm of cells for 24 h at a 
dosage of 10 μM (Huang, R. Z., et al., 2018). The genes downregulated by NF-κB, the mRNA 
levels of BCL-2, Cyclin D1, c-Myc, are all decreased by addition of this compound, from which 
can drive tumor cell into apoptosis.  
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A corresponding experiment in human malignant glioblastoma cells resulted that sulforaphane 
(SFN) treatment can significantly decrease NF-κB expression compared to control cells (Jiang, X., 
et al, 2018). It has also been proved by experiment that SFN can downregulation of the expression 
of antiapoptotic factors BCL-2 and BCL-xL, upregulation of proapoptotic BAX, proteolytic 
activation of caspase-3 (Lan, H, et al., 2017). 
Former studies proved that activation of NF-κB/ p65 will leads to perturbations during the cell 
cycle progression and anti-apoptosis (Ku, J. M., et al, 2015). During the NF-κB signaling cascade, 
phosphorylation of p65 at the serine 536 positions is required for nuclear translocation (Maguire 
et al., 2015). Vam3, a compound derived from Vitis amurensis Rupr., was found to decrease the 
protein levels of TNF-α. Other than that, pretreatment with Vam3 at 2.5 μM and 5 μM reduced the 
phospho-NF-κB p65 expression in colon tissues (Xuan, L., et al., 2016). Similarly, for the bioactive 
compound linarin, proved to regulate cell cycle- and apoptosis-related signals by NF-κB/ p65 
pathways. Linarin down-regulated on p65 expression in glioma cell lines in a dose-dependent 
manner (Zhen, Z. G., et al, 2017). Studies above further confirmed that bioactive compounds can 
modulate NF-κB/ p65 pathways to demonstrate their anti-proliferative and pro-apoptotic activities.  
When considered the docking part for bioactive compounds on NF-κB pathways, the site of DNA- 
binding region (DBR) is also one direction to explore. Researchers working with 1,8- dihydroxy-
4-methylanthracene-9,10-dione (DHMA), isolated from Luffa acutangala, found this compound 
potentially altered the binding affinity between DNA and NF-κB and led to the inhibition of NF-
κB activities (Ramar, V., Pappu, S. 2016). The studies that they conducted proved that DHMA 
shows remarkable affinity with NF-κB p50 subunit and NF-κB- DNA by hydrogen bond 
interaction with active residues like Arg57, His141, Asp239 and Lys24 which are important for 
DNA binding to the DBR of NF-κB. Furthermore, comparing to the NF-κB -DHMA, NF-κB -
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DNA-DHMA complex proved to be a more stable format. Their experiments suggest that DHMA 
might edit the binding abilities between DNA and NF-κB as a potent inhibitor to prevent non-
small cell cancer, which adds another potential mechanism of bioactive compounds reaction with 
NF-κB activities in cancer chemoprevention and therapeutics. 
Nowadays, more and more research around the bioactive compound is concentrated on regulating 
NF-κB pathways, also for its connection between anti-cancer and anti-inflammation. Recent 
researches stated that bioactive compounds can regulate NF-κB pathways mainly via modulating 
TNF-α- induced NF-κB activation and p65 activities, and downregulating on NF-κB targeted gene 
expressions. Further proved the importance and potential for therapy development around 













Fig. 1. Potential bioactive compounds targeted NF-κB signaling pathways 
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Effect of Bioactive Compounds on Autophagy Pathways 
Considering different stages of cancer development, autophagy plays two different roles with pro-
survival or pro-death functions. Under nutrient-limited conditions, pro-survival functions help 
triggering cancer cells survival. This activity of autophagy has been well established in several 
animal models where its suppression is effective in mitigating tumor progression in pancreatic, 
lung, and liver cancers (Guo, J. Y., et al., 2013; Takamura, A., et al., 2011; Yang, Z. J., et al., 
2011). Key mechanisms are: under various stress conditions, including oxidative stress, DNA 
damage, and starvation can trigger autophagy (Shen, H. M., et al., 2011; Marino, G., et al., 2014).; 
as cytoprotective roles against the cytotoxic effect of cancer therapeutics can lead to autophagy 
induction (Wang, C., et al., 2016); autophagy increases cell motility and migration and promotes 
metastasis and invasion (Sharifi, M. N., et al., 2014). While if there is resistance on chemotherapies 
and ionizing radiation, pro-death functions can let autophagy help to kill tumor cells (Panda PK, 
et al., 2015). Mechanisms about its anti-cancer functions include: limits the growth of 
precancerous cells and mitigates cellular oxidative stress, potentially by disposing the damaged 
organelles, especially mitochondria (Mathew, R., et al., 2009); program cell death when massive 
amounts of vesicles accumulate and also maintains genome integrity so as to suppress 
tumorigenesis (Mizushima, N., et al., 2008; Shintani, T., et al., 2004); promotes p62 protein 
degradation, further preventing degradation of autophagosome and its pro-tumorigenic activity 
(Bjørkøy, G., et al., 2005). Multiple studies give positive evidence to support the connection 
between bioactive compounds and induction of autophagy. 
Studies prove that bioactive compound can lead cell death via inhibiting autophagic flux and 
accumulating autophagosome (Lin H. et al., 2018). Physakengose G (PG), a new compound first 
isolated from Physalis alkekengi var. franchetii, is found to increase the intra-lysosomal pH which 
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leads to acidification of lysosomes and further impacts hydrolytic enzyme activity and lysosome 
degradation ability (Liu, et al., 2017). Researchers verified that through the impaired degradation 
of p62 by PG. And further evidence showed that PG-induced LAMP1 accumulation, which 
suggested that PG abolished lysosome acidification and lysosomal membrane permeabilization as 
a way to aggravated cell death.  
A similar response was recorded in another research around Withaferin A (WFA), a bioactive 
compound derived from Withania somnifera, is proved to effectively lead to autophagosome 
formation during Hepatocellular carcinoma (HCC) inhibition (Siddharth, S., et al., 2019). 
Autophagy-related proteins accumulated, especially increased levels of LC3B-II upon drug 
treatment, indicated increased synthesis of autophagosomes with lysosomes to form 
autophagolysosomes after WFA treatment. Uniquely, in this experiment, the autophagic response 
was measured as well, based on the Cathepsin-D expression and activity in HCC cells. Cathepsin-
D is one of the major lysosomal enzyme required for degrading cargo in autolysosomes to amino 
acids, fueling the metabolic reactions or repair processes in the cell (Galluzzi, L., et al., 2017), 
which can be an indicator as a complete autophagic response. 
Interestingly, experiments have demonstrated that autophagy pathway can also regulate other 
cellular signaling pathways to induce cell death and apoptosis. Recent studies have found that 
curcumin can induce autophagy in cancer cells (Shinojima N, et al., 2007). Curcumin treatment 
activated autophagy by increasing protein expression of autophagy marker LC3-II, the ratio of 
LC3-II to LC3-I, and formation of GFP-LC3 puncta, which further demonstrates that LC3 is 
recruited to the autophagosomal membrane during autophagosome formation. On the other hand, 
curcumin treatment can also significantly increased Akt ubiquitination and Akt expression in cell 
insoluble fractionation at an early time-point. Evidence from a relatively early time in their 
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experiment supported that it is possible that Akt is degraded by an autophagy-dependent 
ubiquitination pathway (Guan F., et al, 2016). Their observation leads to a new notion that 
curcumin induces autophagy-dependent Akt degradation leading to suppression of cell 
proliferation and migration.  
This regulation of autophagy was also found and further confirmed in another research about Δ9-
tetrahydrocannabinol (THC, the main active component of marijuana, a compound that triggers 
autophagy-mediated cancer cell death) in glioma cell (Hernández-Tiedra, S., et al., 2016). The 
cannabinoid receptor 1 (CNR1) and cannabinoid receptor 2 (CNR2) are found to bind with THC 
which activates the ceramide synthesis. This may result in lowering the ratio of ceramide to 
dihydroceramide (Cer:dhCer) in the ER which can further transmit to autophagosomes and 
autolysosomes. The ratio changes lead to the induction of ER stress response that causes a TRIB3-
dependent inhibition of the Akt-mTORC1 axis and the subsequent induction of autophagy (Salazar, 
M., et al., 2013). Meanwhile, lysosomal membrane permeabilization (LMP) will be activated 
which leads to cathepsin release and activation of apoptosis and cell death.  
Walsuronoid B, a limonoid compound extracted from Walsura robusta, is found to not only 
initiation cell death through the mitochondria apoptotic pathway, but also lead to lysosomal 
membrane permeabilization (LMP) and the activation of lysosomal proteases cathepsin B and 
cathepsin D, triggering the lysosomal apoptotic pathway (Zhang, C., et al., 2017). Lysosomal 
apoptotic cell death is controlling via the ROS/p53 signaling pathways. When reactive oxygen 
species (ROS) occurrence, LMP is directly started due to ROS has been demonstrated to disrupt 
lysosomal membrane integrity (Johansson A.C., et al., 2010). ROS can trigger p53 activity, which 
also transcriptionally activates the lysosomal proteases cathepsins (Kruiswijk F., et al., 2015).  
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ROS are known to play important roles in various type of cell death, including autophagy (Xu J., 
et al., 2017). In research about marine-derived bioactive compounds, extracts derived from Agelas 
sponges were tested on HCC cells. The accumulation of ROS after the bioactive compound 
treatment is observed (Choi, C., et al., 2018). Evidence showed that ROS cause the increasing of 
ER stress and leads to autophagy in HCC cells. Their research proved that Agelas extracts may 
sensitize HCC cells to IR via ROS overproduction in vitro to further shift the balance in tumor cell 
from survival to death. On the other hand, Pei Yu and their research team found that Physagulide 
P (PP), a new natural compound isolated from Physalis angulate L., induce autophagy in breast 
cancer cells (Yu, P., et al., 2017). Further experiments discovered that is due to the generation of 
reactive oxygen species (ROS) and resulted in c-Jun N-terminal kinases (JNK) activation. Thereby, 
JNK siRNA significantly attenuated PP-triggered autophagy, and ROS scavengers almost 
completely reverse this apoptosis and autophagy. Their results proved the anti-cancer ability of PP 
and further demonstrated the potential of ROS-mediated modulation of autophagy. 
Other than those signaling pathways, the PI3K/Akt/mTOR pathway is another primarily discussed 
pathway for bioactive compounds regulating autophagy. Harmine and harmol, belonging to the 
unsaturated β- carboline alkaloids, proved to exhibit stronger autophagy induction activity among 
other alkaloids (Cui, G., et al., 2019). Autophagy process began with autophagosomes formation, 
then by fusing with the lysosome, the resulting autolysosome begins to degrade the contents. This 
process mediated by various of autophagy- and autophagy-related proteins. Atg8 is one of the key 
factors in the formation of the autophagic membrane, currently as the most widely used 
autophagosome marker (Mizushima, N., et al., 2010), increased sharply after harmine treatment, 
indicating the appearance of autophagy. Atg13 and Atg101, both autophagy-related genes, also 
increased activities after induction of harmine. They interact with UNC-51-like kinase 1 (ULK1) 
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to form a complex, which further couples to the negative autophagy regulator, mTOR complex 1, 
and initiates autophagy (Marino, G., et al., 2014). This reveals a part of a complex signaling 
network involved with bioactive-compounds-induced autophagy. As in research about 
licochalcone A (LicA), not only PI3K/Akt/mTOR pathways related proteins were checked, but 
also more autophagic genes like Beclin-1, Atg5, Atg7, Atg12 which responsible for 
autophagosome biogenesis are tested (Tsai, J. P., et al., 2015). LicA treatment increases the 
expression levels of these related genes in a time-dependent manner in SiHa cells. Their research 
about LicA further demonstrate the complicated mechanism of autophagy and needs to be further 
explored. Therefore, Same pathways were further revealed in research about peiminine, a natural 
bioactive compound extracted from the traditional Chinese medicine Fritillaria thunbergii (Zhao, 
B., et al., 2018). However, researchers found that, during peiminine treatment, the main function 
of Akt and AMPK/ULK1 pathway was used to block autophagic flux in Glioblastoma multiforme 
(GBM) cells since autophagy can facilitate cancer survival under metabolic stress or induce 
autophagic tumor cell death. Studies about Litchi chinensis Sonnerat extracts shows identical 
results which a remarkable increase in the kinase ULK1 when the cell was treated extracts 
(Emanuele, S., et al., 2018). Further evidence showed that light chain3 (LC3), considered as a 
marker of autophagosome presence, was increasing after litchi extracts treatment. A significant 
progressive increase in the autophagic LC3-II form was also observed within 48h. Those results 
further tested the effectiveness of bioactive compound inducing autophagy to tumor cells. 
Furthermore, a study conducted both in vivo and in vitro experiment on an aqueous extract of 
Allspice (AAE) showed consistent results (Zhang, L., et al., 2015). Their in vivo experiment 
proved that AAE greatly inhibited AKT phosphorylation as well as mTOR phosphorylation, which 
further proved to explain the autophagy induction by AAE. Surprisingly, they found that ULK1 
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activation was only found in AAE treated MCF7 cells, but not in MB231 cells. They deduced that 
this might be because of the activation of ULK1 results from changes in different phosphorylation 
sites. Furthermore, Ser757, Ser317, and Ser777 of ULK1 are also found to be the direct 
phosphorylation sites for AMPK in their study. The mechanism of antitumor activity conducted in 
their project shows great correlation with the results of their in vitro studies and was attributed to 
autophagy, without any detectable evidence of apoptosis. 
Former researches found autophagy can be triggered under cancer cell starvation, positively 
regulating through the ERK1/2 pathway. So present research about mechanisms of glycyrrhizin 
(GL), a bioactive compound of licorice, was further digging into that direction (Zhang, X., et al., 
2017). First of all, they proved that GL provoked excessive autophagy in HCC cells. Secondly, 
they further proved that GL can silence the Akt/ mTOR pathway. Since the phosphorylated 
ERK1/2 in HCC cells, it indicated that bioactive compounds can enhance the ERK1/2 activity in 
the induction of excess autophagic cell death pairing with the regulation on PI3K/Akt/mTOR 
pathways.  
Since autophagy can prevent cells from undergoing apoptosis by removing damaged or 
superfluous proteins and organelles, it has been reported that therapies combined with autophagy 
inhibitors to inhibit tumor growth. Studies about WFA showed that WFA-induced autophagy in 
HCC cells is cytoprotective at the functional level as inhibition of autophagy using 3MA (inhibits 
autophagy by blocking autophagosome formation via class III PI3K inhibition), bafilomycin 
(inhibits autophagy by inhibiting the fusion of autophagosomes and lysosomes) or chloroquine 
(inhibits autophagy by elevating lysosomal pH) enhanced the efficacy of WFA treatment. Their 
combination index (CI) analysis showed that WFA and autophagy inhibitors synergistically 
inhibited the growth of HCC cells which indicating a potential combination therapeutic approach 
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involving WFA and clinically viable autophagy inhibitors. Similar results also conducted in the 
AAE research. They wider the selective range of drugs for combined therapy, by using a 
Rapamycin, which the main mechanism is inhibition of mTOR even at very low dose. It has been 
shown to be both chemo-preventive and anti-senescence compound when taken daily at a low, 
non-immune compromising dose (Blagosklonny, M. V., 2013). A combination was proposed by 
the authors, which taking AAE and rapamycin daily may contribute to a novel therapeutic avenue 
for the prevention of cancer. However, more evidence like a defined composition of those bioactive 
compounds should be provided and measured used after experiments. It will still be a challenge to 
give any definitive suggestion for their human use for now. 
In short, it is an efficient way to control tumor cell growth via autophagy pathways. Currently, 
multiple studies put their attention on bioactive compounds with autophagy inducing abilities. 
Bioactive compounds can trigger autophagy pathways through promoting the formation of 
autophagosome and modulating other signal transduction pathways, such as PI3K/Akt/mTOR 
pathway, to initiate autophagy. Since autophagy is essential to balance the cell survive and death, 
the possible influence of bioactive compounds, which target autophagy pathways, on cancer 
























Fig. 2.  Potential bioactive compounds targeted autophagy pathways 
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EFFECT OF BIOACTIVE COMPOUNDS ON HISTONE DEACETYLASE (HDAC) 
Tumor development and progression is the consequence of genetic as well as epigenetic alterations 
of the cell (Mrakovcic, M., et al., 2018). Main function of histone acetyltransferases (HATs) and 
deacetylases (HDACs) is regulating the modification of both histone and non-histone proteins. 
Cancer appears under derailed acetylation-mediated gene expression, which caused by imbalanced 
HDAC expressions. This effect can be reversed through histone deacetylase inhibitors (HDACi) 
treatment via induction of cell cycle arrest, the inhibition of angiogenesis, immunomodulatory 
responses, the inhibition of stress responses, increased generation of oxidative stress, activation of 
apoptosis, autophagy eliciting cell death, and even the regulation of non-coding RNA expression 
in malignant tumor cells (Mrakovcic, M., et al, 2018). 
Recently, more researchers paid more attention to diet and dietary bioactive compounds as a 
regulator of HDACs and as potential anti-cancer substances. A newly-identified flavone, from M. 
bontioides, has extracted bioactive compounds which downregulated the expression of histone 
deacetylase 2 (HDAC2) and HDAC4, leading to increased histone H3 acetylation and p21 
upregulation which will further regulate on cell proliferation to control cell death (Weng J. R., et 
al, 2017). Inhibition of HDAC leads to protein expressions of different histone acetyltransferases 
(HAT) such as CBP, GCN5L2, PCAF, and p300, which found in a cucurbitacin B (CuB), a single 
bioactive triterpenoid compound treatment (Shukla S., et al, 2015). HDACs, especially HDAC1, 
HDAC5, and HDAC6 were found to be considerably downregulated by CuB starting with 60 
nmol/L concentrations in H1299 cells. Results show that HDACs inhibition also helps the 
alternation of the accessibility of various transcriptional factors to the promoters of the tumor 
suppressor genes (TSG) in H1299 cells.  
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Similarly, outcome found in a recent paper focusing on Antrodia cinnamomea (AC) and its anti-
tumor abilities (Chen, Y. C., et al., 2019). The ethanol extract of artificially cultured AC (EEAC) 
was able to modulate epigenetics through the inhibition of HDACs activity mediated histone 
acetylation. Specifically, it inhibited HDACs expression including all HDAC1 (56%), HDAC2 
(29%), HDAC3 (36%) and HDAC4 (48%) with the use of 50 μg/mL. Their results further proved 
that EEAC helps triggering the tumor inhibition via modulating the acetylation and inhibition of 
histone deacetylase. 
Research conducting around SFN recently also pointed out a possible way, about bioactive 
compounds regulating HDAC so as to control tumor cell growth (Martin, S. L., et al, 2018). hTERT, 
the catalytic subunit of telomerase, is found to modulated by the HDAC inhibitor SFN. Due to 
SFN’s HDAC inhibition, it facilitates hyperacetylation and promoting an open chromatin 
formation, allowing known repressor proteins to interact with the regulatory region to regulate the 
expression of hTERT.  
Another nuclear protein, Methylated CpG binding protein 2 (MeCP2), is involved in histone 
modification-related transcriptional repression of specific genes as well (Hansen, J. C., et al, 2010). 
Studies found that curcumin would cause the methylation status of MeCP2 to change in LNCaP 
cells (Shu, L., et al., 2011). Their results confirmed that an inhibited transcription repression can 
be induced by curcumin through decreased binding of MeCP2 to the methylated CpG promoter of 
Neurog1, which showed higher level in a high-grade tumor (Fiegl, H., et al., 2008). MeCP2 can 
help HDAC recruited to gene promoter during the process as well, which leads to chromatin 
conformational change and transcription repression of tumor-suppression genes (Singh, B. N., et 
al., 2010). Meanwhile, the total HDAC activities were also observed with significantly decrease 
which further proved the HDAC inhibitory ability of curcumin treatment.  
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The mechanism of bioactive compounds inducing apoptosis and mediating other tumor cell 
abilities through HDAC inhibition and activation of hyperacetylation is tested in the study about 
plant isoquinoline alkaloid berberine (BBR) treatments in lung cancer cell line (Kalaiarasi, A., et 
al., 2016). According to their evidence, BBR downregulates HDACs by high binding affinity 
against the HDAC family. BBR fits perfectly into the active site region of HDACs, and the ligands 
formed more hydrogen- bond interactions. Western blot revealed that the altered expression of 
class I HDACs and concomitant increase in acetylated histones H3 and H4 upon BBR treatment. 
Combining with other results from this study, through epigenetic modifications by downregulation 
of HDAC enzymes with histone hyperacetylation, BBR regulated sub-G0/G1 cell cycle arrest, 
activates the Bcl-2/Bax family to release of cytochrome c for caspase-mediated apoptosis 
activation and eventually suppresses the invasion and metastasis by hyperacetylation.  
All those evidence supported that regulating HDACs can be a promising target for future cancer 
therapeutics with bioactive compounds. Table 1 concluded several pieces of research' results on 
recent years, which can further strengthen the point that bioactive compound with HDAC 
inhibiting abilities can potentially be accompanied with other mechanisms on modulating tumor 











Table 1. Examples of Anti-Cancer Effects of Bioactive Compounds via HDACs and Autophagy pathways 
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SUMMARY AND FUTURE PERSPECTIVES 
Based on our review, NF-κB, HDACs, and autophagy pathways displayed their significance in 
cancer treatments and their potential usage in future therapeutics. NF-κB, as a crucial target in 
anti-inflammation activities, also found to be valuable in cell apoptotic and autophagy. TNF-α, 
p65, and NF-κB downregulated genes were commonly proved to be regulated after bioactive 
compound treatments. As for autophagy, bioactive compounds usually initiate autophagy by 
leading the autophagosome formation and regulate cellular signal transduction pathways, like 
PI3K/Akt/mTOR and ERK pathways. Bioactive compounds promote the tumor cell from survival 
to death phase through autophagy. Regulation of HDACs activities may be a very promising target 
for future cancer therapeutics with bioactive compounds since more and more evidence supported 
in recent years’ reports. As part of the epigenetic regulatory system, histone acetyltransferases 
(HATs) and deacetylases (HDACs) drive the modification of histone as well as non-histone 
proteins (Mrakovcic, M., et al, 2018). This gives us a possibility of cross-talk between NF-κB, 
HDACs, and autophagy. 
  As a matter of fact, studies have found the cross talk between HDAC and NF-κB. SAHA and 
MS-275, two types of HDACi, is proved to inducting of NF-κB target genes by NF-κB RELA/p65 
hyperacetylation in combination therapy. They were found to activate autophagy and suppress the 
innate immune system in vesicular stomatitis virus oncolysis (Shulak, L., et al, 2014). Similar 
combination treatment, H40, a novel sulfur-containing hydroxamate, with SAHA triggered all 
differentiation, cell cycle arrest, and autophagy by hyperacetylation of histone H3 and 
p21CIP/WAF1 expression (Long, J., et al, 2009). Epigallocatechin-3-gallate (EGCG), proved to 
modulate inflammatory pathways regulated through nuclear factor-kappa B (NF-κB) signaling. 
Recent research observed that when EGCG was added to the cells, it reduced the binding between 
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p65 and p300 to the promoter region of NF-κB-regulated genes with increased recruitment of 
HDAC1/2 (Liu, D., et al., 2016). They found the importance of the balance between HATs and 
HDACs in the NF-κB-mediated inflammatory signaling pathway. However, there is not enough 
experimental evidence to strengthen the connection between HDACs and NF-κB and more future 
studies are necessary. Apart from that, according to a recent review, HDAC inhibition can also 
lead to autophagy via specific pathways. mTOR proved to be a major suppressive regulator of 
autophagy that phosphorylates which inactivates the ULK1 complex, an upstream component of 
the autophagic signaling machinery (Gammoh, N., et al, 2012). The research found that mTOR 
can be inactivated by HDAC inhibitors, therefore restores the function of the ULK1 complex and 
induces autophagy. Meanwhile, HDACi is also discovered to induce autophagy. On a study around 
EEAC, it showed interesting results connecting HDAC with autophagy. Because their results 
proved that EEAC can induced ER stress through IRE1 activation, which regulated anticancer 
protein CHOP expression as well as HDACs inhibition mediated acetyl-histones H3 and H4 
activation, further leading to cell cycle arrest at G1 phase and autophagy induction in the end.  
Therefore, with deeper research around signaling pathways targeting tumor cell death, bioactive 
compounds gain more possibilities for clinical treatment. Currently, abilities to regulate pathways 
in tumor cells like NF-κB, HDAC for bioactive compounds proved to be effective from many 
perspectives. Due to the possible connection between NF-κB, HDAC and autophagy induction, 
future study may dig more into multiple-channel targeted approaches to lead cell apoptosis or 
autophagy. Meanwhile, it is worth noticing that combination therapies gain more effectiveness 
during recent studies. Treatment with low concentrations of combinatorial withaferin A (WA) and 
SFN proved to promote cancer cell death and regulate key epigenetic modifiers in human breast 
cancer cells via cell proliferation and HDAC inhibition (Royston, K., et al, 2017). Hence, as more 
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mechanism of actions of bioactive compounds being revealed in future studies, it is promising to 
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